-
ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT
At the 2025 ASCO Annual Meeting, the West German Study Group (WSG) presented a pooled analysis (Abstract No. 502) of three trials—including the ADAPT TP study—exploring survival outcomes following chemotherapy de-escalation in HER2-positive early breast cancer (eBC). Oncology Frontier invited Prof. Jia Wang and Dr. Jinze Yu from the Second Affiliated Hospital of Dalian Medical…
-
ASCO Highlights | Prof. Wenjin Yin: Who Benefits Most After CDK4/6i Failure? New Biomarker Insights from DESTINY-Breast06 Provide Clearer Answers
There is currently no universally accepted standard treatment for patients who progress after receiving CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i + ET). In the era of precision medicine, both domestic and international guidelines increasingly recommend biomarker-driven treatment strategies. However, the population covered by each biomarker is often limited, creating an urgent clinical need for…
-
Prof. Zefei Jiang Previews Highlights and Reflects on a Decade of Growth in Chinese Oncology
2025 BOC/BOA to Open on July 4th! From BOA to BOC/BOA: Chinese Scholars on the Global Stage Oncology Frontier: BOC/BOA 2025 is just around the corner. Over the years, you’ve…
-
Prof. Jun Guo Invites Global Oncologists to Witness “China’s Rise” and Share the Latest from ASCO
See You in Nanjing for BOC/BOA 2025! Rooted in China, Looking to the World BOC/BOA Celebrates the Rise of Chinese Oncology Oncology Frontier: Could you share the vision behind organizing…
-
YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients
The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation…
-
BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China’s oncology journey. Over the past decade,…
-
YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice
At the recent “Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association,” Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier…
-
Professor Ting Li on TROP2-Targeted ADC Advances in TNBC at ASCO 2025 and Practical Insights for Young Investigators Conducting IIT Studies
Oncology Frontier invited Professor Li for an in-depth interview to discuss major research updates on TROP2 ADCs in the treatment of mTNBC presented at ASCO 2025 and their clinical implications,…
Connecting Medical Expertise through Media